Home Respicardia Inc.

Respicardia Inc.

    Treatment Benefits of the remedē® System Sustained Through 36 Months in Patients with Central Sleep Apnea

    The remedē System, which received U.S. Food and Drug Administration (FDA) approval in October 2017, is a breakthrough implantable system that treats the harmful effects of central sleep apnea by restoring a more normal breathing pattern during sleep.

    RECENT COMMENTS